The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.
October 31st 2024
The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC
November 28th 2023Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.
Interrupting combination treatment with axitinib and avelumab and switching to avelumab maintenance after a response at 36 weeks led to a decrease in treatment-related toxicities and delayed tumor progression in previously untreated patients with metastatic clear cell renal cell carcinoma.
Research Aims to Make Inroads With CAR T-Cell Therapy in Advanced RCC
November 11th 2023Although not immediately practice changing, CAR T-cell therapy has the potential to become a standard of care for patients with advanced renal cell carcinoma following progression on checkpoint inhibitors and VEGF inhibitors.
LITESPARK-013 Data Support RP2D of Belzutifan as Standard Option in Advanced ccRCC
November 11th 2023Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.
Dr Zakharia on Real-World Outcomes With First-Line Axitinib Plus Pembrolizumab in RCC
November 11th 2023Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.
Dr Braun on the Clinical Implications of the CONTACT-03 Trial in RCC
November 10th 2023David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.
Treatments for Translocation RCC Require Novel Therapeutic Targets
November 10th 2023Immune checkpoint inhibitors have been associated with improved outcomes for patients with metastatic translocation renal cell carcinoma; however, novel therapies and therapeutic targets are needed for patients within this histologic subset.